|
|
Current Medical Therapy for Chronic Inflammatory Bowel Diseases
Cited in Scopus: 4
|
Cyrus P. Tamboli
|
Review article
|
June 2007
|
Surgical Clinics of North America
Vol. 87, Issue 3, Pages 697-725 |
|
|
Probiotics for Ulcerative Colitis … Are The Good Bugs Back?
Cited in Scopus: 0
|
Shamita B. Shah
|
Discussion
|
September 2010
|
Gastroenterology
Vol. 139, Issue 3, Pages 1054-1056 |
|
|
 Effect of Once- or Twice-Daily MMX Mesalamine (SPD476) for the Induction of Remission of Mild to Moderately Active Ulcerative Colitis
Cited in Scopus: 89
|
Gary R. Lichtenstein,
Michael A. Kamm,
Prabhakar Boddu,
Natalya Gubergrits,
Andrew Lyne,
Todd Butler,
Kirstin Lees,
Raymond E. Joseph,
William J. Sandborn
et al.
|
Full-length article
|
January 2007
|
Clinical Gastroenterology and Hepatology
Vol. 5, Issue 1, Pages 95-102 |
|
|
The Role of Enteric Microflora in Inflammatory Bowel Disease: Human and Animal Studies with Probiotics and Prebiotics
Cited in Scopus: 17
|
Kevin P. Rioux,
Karen L. Madsen,
Richard N. Fedorak
|
Review article
|
September 2005
|
Gastroenterology Clinics of North America
Vol. 34, Issue 3, Pages 465-482 |
|
|
Mesalamine Inhibits Epithelial β-Catenin Activation in Chronic Ulcerative Colitis
Cited in Scopus: 0
|
Jeffrey B. Brown,
Goo Lee,
Elizabeth Managlia,
Gery R. Grimm,
Ramanarao Dirisina,
Tatiana Goretsky,
Paul Cheresh,
Nichole R. Blatner,
Khashayarsha Khazaie,
Guang–Yu Yang,
Linheng Li,
Terrence A. Barrett
et al.
|
Full-length article
|
February 2010
|
Gastroenterology
Vol. 138, Issue 2, Pages 595-605.e3 |
|
|
Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis
Cited in Scopus: 4
|
William J. Sandborn,
Jaroslaw Regula,
Brian G. Feagan,
Elena Belousova,
Njegica Jojic,
Milan Lukas,
Bruce Yacyshyn,
Piotr Krzeski,
Chyon–Hwa Yeh,
Christi A. Messer,
Stephen B. Hanauer
et al.
|
Full-length article
  
|
December 2009
|
Gastroenterology
Vol. 137, Issue 6, Pages 1934-1943.e3 |
|
|
 Once-Daily, High-Concentration MMX Mesalamine in Active Ulcerative Colitis
Cited in Scopus: 105
|
Michael A. Kamm,
William J. Sandborn,
Miguel Gassull,
Stefan Schreiber,
Lechoslaw Jackowski,
Todd Butler,
Andrew Lyne,
David Stephenson,
Mary Palmen,
Raymond E. Joseph
et al.
|
Full-length article
|
January 2007
|
Gastroenterology
Vol. 132, Issue 1, Pages 66-75 |
|
|
Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis
|
Jonathan R.B. Green*,
Alan J. Lobo‡,
Charles D. Holdsworth‡,
Roger J. Leicester§,
John A. Gibson∥,
Graeme D. Kerr¶,
Humphrey J.F. Hodgson#,
Katharine J. Parkins**,
Michael D. Taylor**,
Abacus Investigator Group
et al.
|
Full-length article
|
January 1998
|
Gastroenterology
Vol. 114, Issue 1, Pages 15-22 |
|
|
Mesalamine derivatives in the treatment of Crohn's disease
Cited in Scopus: 7
|
Laura E Harrell,
Stephen B Hanauer
|
Review article
|
June 2004
|
Gastroenterology Clinics of North America
Vol. 33, Issue 2, Pages 303-317 |
|
|
Prebiotics, Probiotics, and Dietary Fiber in Gastrointestinal Disease
Cited in Scopus: 12
|
Jacqueline Park,
Martin H. Floch
|
Review article
|
March 2007
|
Gastroenterology Clinics of North America
Vol. 36, Issue 1, Pages 47-63 |
|
|
Mesalamine Once Daily Is More Effective Than Twice Daily in Patients With Quiescent Ulcerative Colitis
Cited in Scopus: 9
|
Axel U. Dignass,
Bernd Bokemeyer,
Henning Adamek,
Michael Mross,
Lars Vinter-Jensen,
Norbert Börner,
Jouni Silvennoinen,
Gie Tan,
Marco Oudkerk Pool,
Theo Stijnen,
Peter Dietel,
Tobias Klugmann,
Severine Vermeire,
Aomesh Bhatt,
Henri Veerman
et al.
|
Full-length article
|
July 2009
|
Clinical Gastroenterology and Hepatology
Vol. 7, Issue 7, Pages 762-769 |
|
|
 A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis
Cited in Scopus: 82
|
Geert D’Haens,
William J. Sandborn,
Brian G. Feagan,
Karel Geboes,
Stephen B. Hanauer,
E. Jan Irvine,
Marc Lémann,
Philippe Marteau,
Paul Rutgeerts,
Jurgen Schölmerich,
Lloyd R. Sutherland
et al.
|
Full-length article
|
February 2007
|
Gastroenterology
Vol. 132, Issue 2, Pages 763-786 |
|
|
Enhanced anti-inflammatory effects of a nitric oxide–releasing derivative of mesalamine in rats
|
John L. Wallace,
Nathalie Vergnolle,
Marcelo N. Muscará,
Samuel Asfaha,
Kevin Chapman,
Webb McKnight,
Piero Del Soldato,
Antonio Morelli,
Stefano Fiorucci
et al.
|
Full-length article
|
September 1999
|
Gastroenterology
Vol. 117, Issue 3, Pages 557-566 |
|
|
Probiotics in inflammatory bowel disease: a critical review
Cited in Scopus: 42
|
Cyrus P Tamboli,
Christel Caucheteux,
Antoine Cortot,
Jean-Frédéric Colombel,
Pierre Desreumaux
et al.
|
Review article
|
October 2003
|
Best Practice & Research Clinical Gastroenterology
Vol. 17, Issue 5, Pages 805-820 |
|
|
Progression to Colorectal Neoplasia in Ulcerative Colitis: Effect of Mesalamine
Cited in Scopus: 8
|
Thomas Ullman,
Victoria Croog,
Noam Harpaz,
Sabera Hossain,
Asher Kornbluth,
Carol Bodian,
Steven Itzkowitz
et al.
|
Full-length article
|
November 2008
|
Clinical Gastroenterology and Hepatology
Vol. 6, Issue 11, Pages 1225-1230 |
|
|
AGA Technical Review on the Diagnosis and Management of Colorectal Neoplasia in Inflammatory Bowel Disease
Cited in Scopus: 5
|
Francis A. Farraye,
Robert D. Odze,
Jayne Eaden,
Steven H. Itzkowitz
|
Full-length article
|
February 2010
|
Gastroenterology
Vol. 138, Issue 2, Pages 746-774.e4 |
|
|
The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: A dose-finding study with newly developed mesalamine
Cited in Scopus: 50
|
Wolfgang Kruis,
Simon Bar–Meir,
Janos Feher,
Oliver Mickisch,
Horst Mlitz,
Marek Faszczyk,
Yehuda Chowers,
Gabriella Lengyele,
Agotá Kovacs,
László Lakatos,
Manfred Stolte,
Michael Vieth,
Roland Greinwald,
for The International Salofalk Pellets Study Group
et al.
|
Full-length article
|
January 2003
|
Clinical Gastroenterology and Hepatology
Vol. 1, Issue 1, Pages 36-43 |
|
|
Controversies in Ulcerative Colitis: A Survey Comparing Decision Making of Experts Versus Community Gastroenterologists
Cited in Scopus: 2
|
Brennan M.R. Spiegel,
Wayne Ho,
Eric Esrailian,
Stephan Targan,
Peter D.R. Higgins,
Corey A. Siegel,
Marla Dubinsky,
Gil Y. Melmed
et al.
|
Full-length article
|
February 2009
|
Clinical Gastroenterology and Hepatology
Vol. 7, Issue 2, Pages 168-174.e1 |
|
|
Once-Daily Dosing of Delayed-Release Oral Mesalamine (400-mg Tablet) Is as Effective as Twice-Daily Dosing for Maintenance of Remission of Ulcerative Colitis
Cited in Scopus: 1
|
William J. Sandborn,
Joshua Korzenik,
Bret Lashner,
Jonathan A. Leighton,
Uma Mahadevan,
James F. Marion,
Michael Safdi,
Charles A. Sninsky,
Raman M. Patel,
Keith A. Friedenberg,
Preston Dunnmon,
David Ramsey,
Sunanda Kane
et al.
|
Full-length article
|
April 2010
|
Gastroenterology
Vol. 138, Issue 4, Pages 1286-1296.e3 |
|
|
Medical therapy for ulcerative colitis
|
Niraj Jani,
Miguel D Regueiro
|
Full-length article
|
March 2002
|
Gastroenterology Clinics of North America
Vol. 31, Issue 1, Pages 147-166 |
